Paradigm Biopharmaceuticals Limited (ASX:PAR)

Market Cap	127.38M -34.6%
Revenue (ttm)	n/a
Net Income	-18.77M
EPS	-0.06
Shares Out	439.25M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	698,316
Average Volume	1,079,893
Open	0.3000
Previous Close	0.2900
Day's Range	0.2850 - 0.3000
52-Week Range	0.2550 - 0.6600
Beta	0.24
RSI	39.81
Earnings Date	Feb 25, 2026

About ASX:PAR

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PAR